Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart Failure
NCT07926958, Phase 4, Active not recruiting, Universidade do Porto
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart Failure | ClinicalTrials.gov |
| NCT number | NCT07926958 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 68 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Universidade do Porto | ClinicalTrials.gov |
| Conditions | Heart Failure, Acute Decompensated Heart Failure (ADHF) | ClinicalTrials.gov |
| Interventions | Furosemide, Acetazolamide, Dapagliflozin, Empagliflozin | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in spot urinary sodium concentration at 6 hours | Baseline and 6 hours after the first study treatment administration (day 1) | Change in spot urinary sodium concentration (mmol/L) from baseline to 6 hours after the first study treatment administration. The main comparison is LD+A versus LD alone; the comparison of LD+SGLT2i versus LD alone is secondary. | ClinicalTrials.gov |
| Secondary | Change in spot urinary sodium concentration at day 3 | Baseline and 6 hours after the third study treatment administration (day 3) | Change in spot urinary sodium (mmol/L) from baseline to 6 hours after the third study treatment administration. | ClinicalTrials.gov |
| Secondary | Proportion of patients with spot urinary sodium >70 mmol/L | 6 hours after first administration (day 1) | Percentage of patients achieving spot urinary sodium \>70 mmol/L 6 hours after the first study treatment administration. | ClinicalTrials.gov |
| Secondary | Change in spot urinary potassium | Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3) | Change in spot urinary potassium (mmol/L) from baseline. | ClinicalTrials.gov |
| Secondary | Change in spot urinary magnesium | Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3) | Change in spot urinary magnesium from baseline. | ClinicalTrials.gov |
| Secondary | Change in spot urinary phosphate | Baseline, 6 hours after first administration (day 1) and 6 hours after third administration (day 3) | Change in spot urinary phosphate from baseline. | ClinicalTrials.gov |
| Secondary | Change in estimated glomerular filtration rate (eGFR) | Baseline and day 3 | Change in eGFR (mL/min/1.73 m²) from baseline. | ClinicalTrials.gov |
| Secondary | Change in hemoglobin | Baseline and day 3 | Change in hemoglobin (g/dL) from baseline. | ClinicalTrials.gov |
| Secondary | Change in hematocrit | Baseline and day 3 | Change in hematocrit (%) from baseline. | ClinicalTrials.gov |
| Secondary | Change in serum urea | Baseline and day 3 | Change in serum urea (mg/dL) from baseline. | ClinicalTrials.gov |
| Secondary | Change in serum sodium | Baseline and day 3 | Change in serum sodium (mmol/L) from baseline. | ClinicalTrials.gov |
| Secondary | Change in serum potassium | Baseline and day 3 | Change in serum potassium (mmol/L) from baseline. | ClinicalTrials.gov |
| Secondary | Change in serum chloride | Baseline and day 3 | Change in serum chloride (mmol/L) from baseline. | ClinicalTrials.gov |
| Secondary | Change in systolic blood pressure | Baseline, day 2 and day 3 | Change in systolic blood pressure (mmHg) from baseline. | ClinicalTrials.gov |
| Secondary | Change in diastolic blood pressure | Baseline, day 2 and day 3 | Change in diastolic blood pressure (mmHg) from baseline. | ClinicalTrials.gov |
| Secondary | Change in clinical congestion score | Baseline, day 2 and day 3 | Change in the clinical congestion score from baseline. The clinical congestion score is a composite score based on three items (orthopnea, peripheral edema and jugular venous pressure elevation), each graded from 0 to 3, with a total score ranging from 0 (no congestion) to 9 (maximum congestion). Higher scores indicate a worse outcome (more congestion). | ClinicalTrials.gov |
| Secondary | Proportion of patients with clinical decongestion | Day 3 | Percentage of patients achieving clinical decongestion, defined as a clinical congestion score ≤2 points. The clinical congestion score is a composite score based on orthopnea, peripheral edema and jugular venous pressure elevation, each graded from 0 to 3 (total score 0-9; higher scores indicate more congestion). | ClinicalTrials.gov |
| Secondary | Cumulative intravenous loop diuretic dose | Up to day 3 | Cumulative intravenous furosemide dose (mg) administered up to day 3. | ClinicalTrials.gov |
| Secondary | Incidence of hypokalemia | Baseline to day 3 | Percentage of patients with serum potassium \<3.5 mmol/L. | ClinicalTrials.gov |
| Secondary | Incidence of severe hypokalemia | Baseline to day 3 | Percentage of patients with serum potassium \<3.0 mmol/L. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)